5 New Stock Picks of Billionaire Ken Fisher

Page 5 of 5

1. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)

Number of Hedge Fund Holders: 27    

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) is a biopharma firm that makes and sells drugs for the treatment of neurological diseases and rare disorders. At the end of the third quarter of 2021, Fisher Asset Management owned 267,976 shares in the company worth $37.2 million, representing 0.02% of the portfolio. 

Cantor Fitzgerald analyst Charles Duncan recently raised the price target on Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) stock to $177 from $165 and kept an Overweight rating. 

Among the hedge funds being tracked by Insider Monkey, London-based investment firm Marshall Wace LLP is a leading shareholder in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) with 2.7 million shares worth more than $265 million. 

In its Q1 2021 investor letter, Baron Funds, an asset management firm, highlighted a few stocks and Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) was one of them. Here is what the fund said:

“Biohaven Pharmaceutical Holding Company Ltd. is a biotechnology company dedicated to neurologic drug discovery. It launched its lead asset, migraine medication Nurtec, last year, and the company is transitioning towards profitability. Shares declined when Biohaven issued a secondary offering in March that took investors by surprise and seemed early in relation to an expected second indication for Nurtec in the prophylactic prevention of migraine, which expands its market. We exited our position.”

You can also take a peek at 10 Cheap Small-Cap Stocks to Buy and 10 Penny Stocks with Upcoming Growth Catalysts.

Page 5 of 5